Eosinophilic granulomatosis with polyangiitis: a challenge for differential  diagnosis by Lechuga Ortiz, Jorge Andrés & Forero Illera, Elías Gonzalo
Vol. 34, N° 2, 2018
ISSN 0120-5552
eISSN 2011-7531














































Eosinophilic granulomatosis with polyangiitis: 
a challenge for differential diagnosis
Granulomatosis eosinofílica con poliangitis: 
un desafío para el diagnóstico diferencial
Elías Forero Illera1, Jorge Lechuga Ortiz2
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss 
syndrome, is a rare small and medium vessels vasculitis, consisting of asthma, migratory 
pulmonary infiltrates and eosinophilia. Its low occurrence makes it difficult to achieve an 
early diagnosis, and hence a directed treatment in order to control it and avoid complications. 
We report a 31 year-old man with refractary asthma, who developed arthritis and multiplex 
mononeuritis. Before EGPA´s diagnosis, he had just received asthma treatment (steroids, 
bronchodilators, antileukotriene and omalizumab); but once EGPA is confirmed and correct 
treatment was started, there was a remarkable clinical improvement.     
Key words: Churg Strauss, Vasculitis, Allergic granulomatosis, Antineutrophil cyto-
plasmic antibody.
Resumen
La granulomatosis eosinofílica con poliangitis (EGPA), anteriormente conocida como síndro-
me de Churg-Strauss, es una vasculitis poco frecuente de vasos pequeños y medianos, que 
consiste en asma, infiltrados pulmonares migratorios y eosinofilia. Su baja aparición dificulta 
el diagnóstico precoz y, por lo tanto, un tratamiento dirigido para controlarlo y evitar compli-
caciones. Presentamos a un hombre de 31 años con asma refractaria, que desarrolló artritis y 
mononeuritis múltiple. Antes del diagnóstico de EGPA, acababa de recibir tratamiento para 
el asma (esteroides, broncodilatadores, antileucotrienos y omalizumab); pero una vez que se 
confirmó la EGPA y se inició el tratamiento correcto, hubo una mejoría clínica notable.
Palabras clave: Churg Strauss, vasculitis, granulomatosis alérgica, anticuerpo cito-
plasmático antineutrófilo.
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INTRODUCTION
In aggressive and rare diseases, a rapid diag-
nosis and therefore, a directed treatment im-
proves substantially the prognosis of patients. 
EGPA requires for its diagnosis a high clinical 
suspicion, because the majority of cases can 
mimic diseases like asthma for several years. 
It is important to remark key points that allow 
medical doctors to have EGPA in mind, in order 
to achieve a timely treatment and prevent the 
progression of the disease that could be fatal. 
CLINICAL CASE
A 31 year-old man was directed to the Rheu-
matologist for 4 months of swollen and tender 
joints in hands, elbows, shoulders and ankles; 
in addition to 30 minutes morning stiffness. 
He had also had frontal headache and hands 
paresthesias for 2 months. 
The patient had a history of asthma, with poor 
response to treatment since he was 9 years old. 
He received prednisone, beclometasone, salbu-
tamol, ipratropium bromide until 22 years of 
age, time when he started to use salmeterol/
fluticasone plus montelukast, because of the 
uncontrolled asthma. Once the disease got 
worse in symptoms in spite of the described 
treatment, omalizumab was started.
Relevant exams showed: positive rheumatoid 
factor (100 UI/dL [reference<30 UI/dL); Blood 
eosinophils count: 7.830/mm3 (representing 
34% of total white blood cells); Erythrocyte se-
dimentation rate: 78 mm/hour (reference <30 
mm/hour); and C-reactive protein: 12 mg/L 
(reference <3 mg/L). Antinuclear antibodies and 
extractable nuclear antigens antibodies were ne-
gative. C3 and C4 fractions were normal. Initially, 
the patient received a diagnosis of Rheumatoid 
arthritis (RA), and underwent therapy with me-
totrexate 15 mg per-week plus prednisone 5 
mg/day without improvement.
For assurance reasons, the patient arrived to 
our center after 6 months of RA diagnosis. 
By that time, physical examination showed: 
normal respiratory sounds; hypothenar emi-
nence atrophy in left hand with decreased 
muscular strength of flexors and extensors 
(Figure  1);  left forearm and hand dysethe-
sias; and synovitis in elbows, wrists, and 
2nd/3rd/4th metacarpophalangeal joints.
In summary, it is a case of a patient with 
uncontrolled asthma since childhood, ar-
thritis, peripheral neuropathy, eosinophilia, 
positive rheumatoid factor and elevated 
acute phase reactants. Therefore, we asked 
for neurology consultation and some com-
plementary studies. 
An electromyogram test & nerve conduction 
study of upper extremities showed sensitive 
and motor neuropathy, with predominance 
of axonal involvement, more severe in the 
left ulnar nerve, basically related to multiple 
mononeuropathy. Magnetic resonance of the 
brain was normal, however it demonstrated 
pansinusitis. Chest tomography showed peri-
bronchial enlargement, cylindrical bronchiec-
tasis and subpleural emphysema (Figure 2).
6 months later, the patient developed purpuric 
skin lesions in feet, compatible with vasculitis 
(Figure 3). This last finding in addition to un-
controlled asthma, pansinusitis, eosinophilia 
and multiple mononeuropathy led to think 
about EGPA diagnosis. Antineutrophil cyto-
plasmic antibodies were weakly positives 
(ANCA-P titers 1:40). It was not possible to 
take specific antibodies (anti-proteinase 3 and 
anti-myeloperoxidase), and patient rejected a 
skin biopsy. In spite of low ANCA-P titers, ba-
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sed on the context of clinical case, the antibodies 
were taken into account for EGPA diagnosis, 
highlighting that they are positive just in 40-
60% of cases and they are not specific for EGPA. 
Omalizumab was suspended. It was ordered 
prednisone 50 mg/day plus cyclophosphamide 
600 mg/m2/month (6 doses). 
Once the treatment started, patient improves 
arthritis, skin lesions, asthma symptoms and 
acute phase reactants. When clinical, radiologi-
cal and para-clinical improvement was achie-
ved, prednisone was lowered progressively 
10 mg/week until 10 mg/day dose. Patient 
finished the 6 doses of cyclophosphamide 
successfully; and nowadays, he continues in 
medical control, without reactivation of EGPA, 
and persisting only with blood eosinophilia. 
DISCUSSION
Churg-Sttrauss syndrome, since 2012 EGPA 
(1), is a medium and small vessels vasculi-
tis, ANCA positive, with prevalence rate of 
6,8 (IC95%: 1,8-17,3) per million-patients/
year, and incidence of 0-14 cases per million-
patients/year in asthmatic groups (2-4). In 
Colombia, there are cases reported in Cali, 
Bogotá, Medellín and Huila (5-8); but any in 
the Caribbean Coast. EGPA diagnostic criteria 
are listed in Table 1. EGPA affects mainly lungs 
and skin, but also kidney, heart, gastrointesti-
nal tract and nervous system.
EGPA has 3 phases, not always distinguisha-
ble (9-12): 
a) Prodromic: usually at 20-30 year-old, with 
allergic manifestations (rhinitis, dermatitis, 
asthma [present in 90% of EGPA]). 
b) Eosinophilic: often after 30´s, with elevated 
eosinophils in blood (Eo>10% of total blood 
cells, or Eo count>500/mm3) and organs 
like lungs. Eosinophilia may persist, even 
with disease control.  
c) Vasculitic: appears after 8 to 10 years 
of symptoms onset. Here, 40% of patients 
debut with transitory pulmonary infiltrates 
(because of pulmonary vasculitis), asthma 
and eosinophilia. In this phase the mortality 
increases, due to necrotizing granulomatous 
vasculitis of multiple organs; and also leads 
to beginning of fever, arthritis, anorexia and 
weight loss. 
Although bronchiectasis is more related 
to infections (tubeculosis, fungi), inflam-
matory pneumonitis, immunodeficiencies 
or systemic diseases (lupus, RA); in EGPA 
it is not known if bronchiectasis is produced 
by the disease or the immunosuppresion of 
its treatment. (13-14) 
Regularly, it is difficult to achieve an adequa-
te control in asthma related to EGPA. Asthma 
severity increases with the onset of the vas-
culitic phase, which suggests EGPA could be 
present. Corticosteroid for asthma can delay 
the beginning of vasculitic phase, which may 
suddenly appear with the decreasing or the 
suspension of corticosteroids.(15). There 
are data suggesting that EGPA could be an 
adverse effect of antileukotrienes, especially 
3-12 months after its onset; however, there is 
not a proved causal relationship. This could 
be more related to the use of antileukotrienes 
for uncontrolled asthma (moment when is 
it possible to think in EGPA diagnosis) or 
with reducing of corticosteroids dose when 
antileukotrienes are started (which can pre-
cipitate the vasculitic phase onset). (16-18)
This clinical case shows the evolution of 
a male with asthma since childhood, with 
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EGPA diagnosis after 22 years. Difficult-to-
treat asthma, pansinusitis, eosinophilia, pul-
monary infiltrates, multiple mononeuropathy 
and cutaneous vasculitis in conjunction were 
the key points of EGPA diagnosis. Seropositi-
ve arthritis in EGPA is especially interesting, 
because it is not described in the review that 
was made for the case discussion. 
EGPA should be suspected in late-onset or 
difficult-to-treat asthma, eosinophilia and 
neuropathy, remembering that the vasculitic 
phase may be delayed with corticosteroids for 
asthma; and may be facilitated after corticoste-
roids suspension or reduction. Early diagnosis 
leads to timely initiation of treatment that 
prevents progression to more severe stages.
Funding: Universidad del Norte. 
Conflict of interests: None to declare
REFERENCES
1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid 
MC, Ferrario F, et al. 2012. Revised Inter-
national Chapel-Hill Consensus Conferen-
ce Nomenclature of Vasculitides. Arthritis 
Rheum. 2013;65(1):1-11.
2. Martin RM, Wilton LV, Mann RD. Prevalence 
of Churg-Strauss syndrome, vasculitis, eosi-
nophilia and associated conditions: retros-
pective analysis of 58 prescription-event mo-
nitoring cohort studies. Pharmacoepidemiol 
Drug Saf 1999;8(3):179-189.
3. Louglin JE, Cole JA, Rothman KJ, Johnson 
ES. Prevalence of serious eosinophilia and 
incidence of Churg-Strauss syndrome in a 
cohort of asthma patients. Ann Allergy Asth-
ma Immunol 2002;88(3):319-325.
4. Harrold LR, Andrade SE, Go A, Buist AS, 
Eisner M, Volmer WM, et al. Incidence of 
Churg-Strauss syndrome in asthma drug 
users: a population- based perspective. J 
Rheumatol. 2005;32(6):1076-1080.
5. López Rengifo DM, Contreras Zúñiga E, 
Osio LF. Síndrome de Churg- Strauss. Rev 
Col Reumatol 2007;14(3):237-240.
6. Sánchez Morales EA, Saavedra Rodríguez 
A, Henao Riveros S. Síndrome de Churg-
Strauss. Rev Fac Med UN 2002;50(3):138-146.
7. Restrepo M, González LA, Vásquez G, Lon-
doño D. Síndrome de Churg- Strauss: a pro-
pósito de un caso con manifestaciones poco 
usuales. Rev Col Reumatol 2009;16(1):112-
119.
8. Acevedo JR, Londoño JC, Iglesias A, Mén-
dez O. Angeítis y granulomatosis alérgica 
(síndrome de Churg-Strauss): Presentación 
de un caso sin asma. Acta Med Colomb 
1992;17(6):437-440.
9. Meziane H, Maaekel ML, Vachier I, Bousquet 
J, Chanez P. Sputum eosinophilia in Churg-
Strauss síndrome. Resp Med 2001;95:7999-
7801.
10. Guillevin L, Cohen P, Gayraud M, Lhote 
F, Jarrousse B, Casassus P. Churg-Strauss 
syndrome. Clinical study and long-term fo-
llow-up of 96 patients. Medicine (Baltimore) 
1999;78(1):26.
11. Lanham JG, Elkon KB, Pusey CD, Hughes 
GR. Systemic vasculitis with asthma and eo-
sinophilia: a clinical approach to the Churg-
Strauss syndrome. Medicine (Baltimore). 
1984;63(2):65
12. Churg A, Brallas M, Cronin SR, Churg J. 
Formes frustes of Churg-Strauss syndrome. 
Chest. 1995;108(2):320.
13. Nathani N, Little MA, Kunst H, Wilson D, 
Thickett DR. Churg–Strauss syndrome and 
leukotriene antagonist use: a respiratory 
perspective. Thorax 2008;63:883-888.
14. Guilpain P, Pagnoux C, Lhote F, Mouthon 
L, Guillevin L. Antileukotrienes and Churg-
Strauss síndrome. Presse Med. 2007; 36(5-
Pt2):890-894.
15. McDanel DL, Muller BA. The linkage bet-
ween Churg-Strauss syndrome and leuko-
triene receptor antagonists: fact or fiction?. 
Ther Clin Risk Manag. 2005;1(2):125–140.
